Keloid

United States Scar Treatment Market 2018-2023 - Market Size is Expected to Reach $34.9 Billion

Retrieved on: 
Wednesday, August 8, 2018
Fiction, Dermatology, Skin, Healing, Scar, RTT, Keloid, Hypertrophic scar, Acne

The "U.S. Scar Treatment Market by Type of Treatment, by Type of Scar, by End User - Market Size, Share, Development, Growth, and Demand Forecast, 2013 - 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "U.S. Scar Treatment Market by Type of Treatment, by Type of Scar, by End User - Market Size, Share, Development, Growth, and Demand Forecast, 2013 - 2023" report has been added to ResearchAndMarkets.com's offering.
  • Based on the type of scar, the scar treatment market is categorized into post-surgical scar, acne scar, keloid and hypertrophic scar, contracture scar, and stretch mark.
  • Based on end user, the scar treatment market is categorized into home-use, hospitals dermatology clinics and others.
  • Globally, North America accounted for the largest share of the scar treatment market, with 38.5% share in 2017.

Sensus Healthcare Receives FDA 501(k) Clearance to Market Next-Generation SRT-100+ Superficial Radiation Therapy for Treating Non-Melanoma Skin Cancer and Keloids

Retrieved on: 
Thursday, August 2, 2018
RTT, SensUs, Keloid, Melanoma, Dermatology, Skin cancer, Cancer, Skin, Biology, Medicine

This represents the technology of the future when it comes to treating NMSC and keloids safely and effectively."

Key Points: 
  • This represents the technology of the future when it comes to treating NMSC and keloids safely and effectively."
  • Most importantly, this 501(k) market clearance uniquely positions Sensus to fuel continued innovation in the clinical dermatology space."
  • Sensus Healthcare, Inc. is a medical device company that is committed to providing non-invasive and cost-effective treatment for non-melanoma skin cancers and keloids.
  • Sensus also offers Sensus Laser Systems, three next-generation devices that showcase the latest in technology and function for the aesthetic dermatology market.

Sensus Healthcare to Host Second Quarter 2018 Financial Results and Business Update Conference Call on August 2, 2018

Retrieved on: 
Tuesday, July 24, 2018
RTT, SensUs, Keloid, Skin cancer, Melanoma, Dermatology, Cancer, Toll-free telephone number, Skin, Biology, Integumentary system

In addition, management will provide a business update and a discussion on recent and upcoming milestones.

Key Points: 
  • In addition, management will provide a business update and a discussion on recent and upcoming milestones.
  • To access the conference call, the dial-in numbers are 855-940-9473 (U.S. Toll Free), 412-317-5220 (International) and 855-669-9657 (Canada Toll Free).
  • Sensus Healthcare, Inc., is a medical device company that is committed to providing non-invasive and cost-effective treatment for non-melanoma skin cancers and keloids.
  • Sensus recently launched Sensus Laser Systems, three next-generation devices that showcase the latest in technology and function for the aesthetic dermatology market.

Sensus Healthcare Announces Strategic Agreement with SkinCure Oncology

Retrieved on: 
Thursday, July 12, 2018
RTT, Biosensors, SensUs, Keloid, Cancer, Dermatology, Melanoma, Biology, Science, Medicine

"Sensus' strategic relationship with SkinCure Oncology is representative of our customer-centric approach in supporting the dermatology community, not to mention a valuable resource to further expand our market position," said Joe Sardano, chairman and chief executive officer of Sensus Healthcare.

Key Points: 
  • "Sensus' strategic relationship with SkinCure Oncology is representative of our customer-centric approach in supporting the dermatology community, not to mention a valuable resource to further expand our market position," said Joe Sardano, chairman and chief executive officer of Sensus Healthcare.
  • "We entered into this agreement with Sensus based on our belief in its technology and market lead in IGSRT delivery systems," added Kerwin Brandt, CEO, Skincure Oncology.
  • Sensus Healthcare, Inc., is a medical device company that is committed to providing non-invasive and cost-effective treatment for non-melanoma skin cancers and keloids.
  • Sensus recently launched Sensus Laser Systems, three next-generation devices that showcase the latest in technology and function for the aesthetic dermatology market.

Sensus Healthcare to Participate in Panel Discussion at the Cantor Fitzgerald Dermatology & Aesthetics Summit

Retrieved on: 
Tuesday, June 12, 2018
RTT, SensUs, Keloid, Melanoma, Dermatology, Cancer, Skin cancer, Skin, Biology, Medicine

The Summit is being held at the Westin Grand Central Hotel.

Key Points: 
  • The Summit is being held at the Westin Grand Central Hotel.
  • Sensus Healthcare, Inc., is a medical device company that is committed to providing non-invasive and cost-effective treatment for non-melanoma skin cancers and keloids.
  • To date, SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in thousands of patients.
  • Sensus recently launched Sensus Laser Systems, three next-generation devices that showcase the latest in technology and function for the aesthetic dermatology market.

Sensus Healthcare to Host First Quarter 2018 Financial Results and Business Update Conference Call on May 3, 2018

Retrieved on: 
Thursday, April 26, 2018
RTT, SensUs, Keloid, Skin cancer, Melanoma, Dermatology, Cancer, Toll-free telephone number, Skin, Biology, Integumentary system

In addition, management will provide a business update and a discussion on recent and upcoming milestones.

Key Points: 
  • In addition, management will provide a business update and a discussion on recent and upcoming milestones.
  • To access the conference call, the dial-in numbers are 855-940-9473 (U.S. Toll Free), 412-317-5220 (International), and 855-669-9657 (Canada Toll Free).
  • Sensus Healthcare, Inc., is a medical device company that is committed to providing non-invasive and cost-effective treatment for non-melanoma skin cancers and keloids.
  • Sensus recently launched Sensus Laser Systems, three next-generation devices that showcase the latest in technology and function for the aesthetic dermatology market.

Sensus Healthcare Appoints Dr. Isabelle Raymond as Vice President, Clinical Development

Retrieved on: 
Tuesday, May 8, 2018
RTT, Skin cancer, Melanoma, Keloid, SensUs, Cancer, Dermatology, Skin, Biology, Integumentary system

BOCA RATON, Fla., May 8, 2018 /PRNewswire/ --Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), announced the appointment of Dr. Isabelle Raymond, PhD, as Vice President, Clinical Development.

Key Points: 
  • BOCA RATON, Fla., May 8, 2018 /PRNewswire/ --Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), announced the appointment of Dr. Isabelle Raymond, PhD, as Vice President, Clinical Development.
  • Dr. Raymond, who will report to Joe Sardano, Sensus CEO, brings 14 years of medical device and pharmaceutical industry experience to the Company.
  • Sensus Healthcare, Inc., is a medical device company that is committed to providing non-invasive and cost-effective treatment for non-melanoma skin cancers and keloids.
  • Sensus recently launched Sensus Laser Systems, three next-generation devices that showcase the latest in technology and function for the aesthetic dermatology market.

Sensus Healthcare Expands International Business to Meet Rising Patient Demand for Non-Invasive Skin Cancer and Keloid Treatments

Retrieved on: 
Thursday, April 19, 2018
RTT, SensUs, Melanoma, Keloid, Cancer, Dermatology, Skin cancer, Skin, Biology, Integumentary system

Rick Golin, Executive Vice President of Oncology and International Sales, will spearhead this expansion, overseeing all international distributors.

Key Points: 
  • Rick Golin, Executive Vice President of Oncology and International Sales, will spearhead this expansion, overseeing all international distributors.
  • "Given the simultaneous growth of Sensus' geographic footprint and product offerings, we're in a perfect position to meet this demand.
  • Sensus Healthcare, Inc., is a medical device company that is committed to providing non-invasive and cost-effective treatment for non-melanoma skin cancers and keloids.
  • Sensus recently launched Sensus Laser Systems, three next-generation devices that showcase the latest in technology and function for the aesthetic dermatology market.